Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB:AWKNF), a biotech company developing psychedelic medicines for addiction, has received approval to launch a human study looking into the effects of ketamine in gambling addiction.
The early-stage study will analyze if ketamine administration can modify reward memories associated with gambling, and if successful, will serve as the basis for possible clinical trials using the same method in improving gambling addiction.
While Awakn has begun recruiting human participants, this study is not a clinical trial, explained Prof. Celia....More>>>
Resurgent Biosciences, a subsidiary of Goodness Growth Holdings, Inc. (CSE:GDNS) (OTCQX:GDNSF), is launching a survey study that will look into the varying effects of entheogen and psychedelic experiences for therapeutic, religious and spiritual purposes.
The goal of the company is to understand the naturalistic use of entheogens and other substances typically used for healing in specific cultural and spiritual contexts.
Goodness Growth recently changed its name from Vireo Health in a move to encompass the psychedelics and natural medicine space, expanding beyond its cannabis....More>>>